Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline)

Annals of the New York Academy of Sciences

Volumn 786, Issue , 1996, Pages 379-390

  Wu, Ruey Meei ^a,b   Murphy, Dennis L ^a   Chiueh, Chuang C ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; HYDROXYL RADICAL; SELEGILINE;

ANIMAL EXPERIMENT; CONFERENCE PAPER; MALE; NERVE CELL; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; RAT; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 0029779755     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb39078.x     Document Type: Conference Paper

References (39)

1. KNOLL, J., Z. ECSERY, K. KELEMEN, J. NIEVEL & B. KNOLL. 1965. Phenylisopropylmethyl-propinylamine (E-250), a new psychic energizer. Arch. Int. Pharmacodyn. Ther. 155: 154-164.
2. ELSWORTH, J. D., V. GLOVER, G. P. REYNOLDS, M. SANDLER, A. J. LEES & P. PHUAPRADIT. 1978. (-)-Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect." Psychopharmacology 578: 33-78.
3. BIRKMAYER, W., P. RIEDERER, L. AMBROZI & M. B. H. YOUDIM. 1977. Implications of combined treatment with Madopar® and deprenyl in Parkinson's disease. Lancet i: 439-444.
4. GOLBE, L. I., A. N. LIEBERMAN, M. D. MUENTER, J. E. AHLSKOG, G. GOPINATHAN, A. N. NEOPHYTIDES, S-H. FOO & R. C. DUVOISIN. 1988. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin. Neuropharmacol. 2: 45-55.
5. CHIBA, K., A. TREVOR & N. CASTAGNOLI, JR. 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120: 574-578.
6. KNOLL, J. 1986. The pharmacology of (-)deprenyl. J. Neural. Transm. (Suppl.) 22: 75-89.
7. FINNEAGAN, K. T., J. J. SKRATT, I. IRWIN, L. E. DELANNEY & J. W. LANGSTON. 1990. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur. J. Pharmacol. 184: 119-126.
8. COHEN, G. & M. B. SPINA. 1989. Deprenyl suppressed the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26: 689-690.
9. KNOLL, J., J. DALLO & T. T. YEN. 1989. Striatal dopamine, sexual activity and life span. Longevity of rats treated with (-)deprenyl. Life Sci. 45: 525-531.
10. KITANI, K., S. KANAI, Y. SATO, M. OHTA, G. O. IVY & M. C. CARRILLO. 1993. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci. 52: 281-288.
11. SALO, P. T. & W. G. TATTON. 1992. Deprenyl reduces the death of motor neurons caused by axotomy. J. Neurosci. Res. 31: 394-400.
12. PARKINSON STUDY GROUP. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Eng. J. Med. 328: 176-183.
13. MANGON, A., M. P. GRASSI, L. FRATTOLA, R. PIOLTI, S. BASSI, A. MOTTA, A. MARCONE & S. SMIRNE. 1991. Effects of a MAO-B inhibitors in the treatment of Alzheimer's disease. Eur. Neurol. 31: 100-107.
14. BERRY, M. D., A. V. JUORIO & I. A. PATERSON. 1994. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog. Neurobiol. 44: 141-161.
15. KNOLL, J. 1989. The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol. Scand. 126: 83-91.
16. CARRILLO, M. C., K. KITANI, S. KANAI, Y. SATO, K. MIYASAKA & G. O. IVY. 1994. (-)Deprenyl increases activities of superoxidase and catalase in certain brain regions in old male mice. Life Sci. 54: 975-981.
17. SENIUK, N. A., J. T. HENDERSON, W. G. TATTON & J. C. RODER. 1994. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R (-)-deprenyl. J. Neurosci. Res. 37: 278-286.
18. CHIUEH, C. C., S. J. HUANG & D. L. MURPHY. 1994. Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J. Neural Transm. (Suppl.) 41: 189-196.
19. CHIUEH, C. C., S. J. HUANG & D. L. MURPHY. 1992. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 11: 346-348.
20. FAHN, S. & G. COHEN. 1992. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32: 804-812.
21. CHIUEH, C. C., H. MIYAKE & M. T. PENG. 1993. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. In Advances in Neurology: Parkinson's Disease: from Basic Research to Treatment. H. Narabayashi, T. Nagatsu, N. Yanagisawa & Y. Mizuno, Eds. Vol. 60: 251-258. Raven Press. New York.
22. +. Free Radical Biol. Med. 13: 581-583.
23. PAXINOS, G. & C. WATSON. 1986. The Rat Brain in Stereotaxic Coordinates, 2nd Edit. Academic Press. San Diego.
24. +. J. Neural Transm. 74: 75-86.
25. CHIUEH, C. C., D. L. MURPHY, H. MIYAKE, K. LANG, P. TULSI & S. J. HUANG. 1993. Hydroxyl free radical formation reflected by salicylate hydroxylation and neuromelanin: in vivo markers for oxidation injury of nigral neurons. Ann. N.Y. Acad. Sci. 679: 370-375.
26. +. J. Neural Trasm. 89: 139-145.
27. + by deprenyl. Ann. N.Y. Acad. Sci. 738: 214-222.
28. HEINONEN, E. H. & R. LAMMINTAUSTA. 1991. A review of the pharmacology of selegiline. Acta Neurol. Scand. 84(Suppl. 136): 44-59.
29. SZOKO, E., G. BATHORY, K. TEKES & K. MAGYAR. 1990. Effect of l-deprenyl on lipid peroxidation in rat brain homogenate. Eur. J. Pharmacol. 183(4): 1549-1549.
30. THOMAS, C. E., R. J. DINERSTEIN & D. F. OHLWEILER. 1994. In vitro trapping of free radicals by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A. Soc. Neurosci. Abstr. 20: 412 (#175.4).
31. KNOLL, J., V. TOTH, M. KUMMER & J. SUGAR. 1992. (-)Deprenyl and (-)parafluorodeprenyl treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. Mech. Ageing Dev. 63: 157-163.
32. + in vivo. Eur. J. Pharmacol. 243: 241-247.
33. ROY, E. & P. J. BEDARD. 1993. Deprenyl increases survival of rat foetal nigral neurons in culture. NeuroReport 4: 1183-1186.
34. VIZUETE, M. L., V. STEFFEN, A. AYALA, J. CANO & A. MACHADO. 1993. Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum. Neurosci. Lett. 152: 113-116.
35. TATTON, W. G. & C. E. GREENWOOD. 1991. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30: 666-672.
36. FINGERG, J. P. M., M. TENNE & M. B. H. YOUDIM. 1981. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol. 73: 65-74.
37. TOLLIVER, T. I., S. J. HUANG, C. C. CHIUEH, D. L. MURPHY & J. M. TOLLIVER. 1993. Comparison of deprenyl (selegiline) and MPP on cocaine-sensitive dopamine uptake sites. Soc. Neurosci. Abstr. 19: 402 (#164.7).
38. FANG, J. & P. H. YU. 1994. Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. J. Neuropharmacol. 33: 763-768.
39. WU, R-M., D. L. MURPHY & C. C. CHIUEH. 1995. Neuronal protective and rescue effects of deprenyl against MPP dopaminergic toxicity. J. Neural Transm. (Gen. Sect.) 100: 53-61.